Despite its anti-obesity effect, INT-767 fails to reverse diet-induced glucose intolerance or insulin insensitivity, suggesting that INT-767 may not be useful for treatment of type II diabetes. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.